Latest News and Press Releases

Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret. Omsætningen forventes nu at stige med 12-14% i lokale valutaer (mod tidligere:...

Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue is now expected to grow by 12-14% in local currencies (previously...

ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in...

Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at det britiske Medicines and Healthcare Products Regulatory Agency (MHRA) har godkendt EURneffy® 2 mg til behandling af anafylaksi hos...

Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for...

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely...

Lægemiddelstyrelsen har netop godkendt Itulazax, den første tabletbaserede allergivaccination til behandling af børn og unge i alderen fem til 17 år med træpollenallergi i Danmark. Som grundlag for...

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK...

ALK (ALKB:DC / OMX: ALK B) today announced that the company is participating at the Jefferies Global Healthcare Conference 2025 in New York City taking place from 3 - 5 June 2025. Claus Steensen...

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and...